AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2025
Apr 9, 2025
31100_dirs_2025-04-09_118a72b8-2165-4c7a-a3af-df314a8b2a1f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-04-07
Reporting Person: GUGGENHIME ANDREW (PRESIDENT AND CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-07 | Common Stock | M | 4777 | $20.93 | Acquired | 131950 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-07 | Stock Option (right to buy) | $20.93 | M | 4777 | Disposed | 2031-03-31 | Common Stock (4777) | Direct |
Footnotes
F1: Stock Option is fully vested and exercisable.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24